Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon- -2c in patients with advanced colorectal cancer: final results of a randomised phase III study

Author： Hausmaninger H.   Moser R.   Samonigg H.   Mlineritsch B.   Schmidt H.   Pecherstorfer M.   Fridrik M.   Kopf C.   Nitsche D.   Kaider A.   Ludwig H.  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.35, Iss.3, 1999-03, pp. : 380-385

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase III Study of Recombinant Interleukin-2, 5-Fluorouracil and Leucovorin Versus 5-Fluorouracil and Leucovorin in Patients with Unresectable or Metastatic Colorectal Carcinoma

By Heys S.D.   Eremin O.   Ruggeri E.M.   Pein F.   Rainer H.   Oskam R.   de Peuter R.A.   Palmer P.A.   Franks C.R.  

European Journal of Cancer, Vol. 31, Iss. 1, 1995-01 ,pp. : 19-25

Elsevier

Access to resources Recommend Favorite

Modulation of 5-Fluorouracil with Methotrexate and Low-dose N-(phosphonacetyl)-l-aspartate in Patients with Advanced Colorectal Cancer. Results of a Phase II Study

By Kohne C.-H.   Harstrick A.   Hiddemann W.   Schoffski P.   Wilke H.   Bokemeyer C.   Dorken B.   Schmoll H.-J.  

European Journal of Cancer, Vol. 33, Iss. 11, 1997-10 ,pp. : 1896-1899

Elsevier

Access to resources Recommend Favorite

Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer

By Goto Ayumu   Yamada Yasuhide   Hosokawa Ayumu   Ura Takashi   Arai Tatsuhiro   Hamaguchi Tetsuya   Muro Kei   Shimada Yasuhiro   Shirao Kuniaki  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 364-368

Springer Publishing Company

Access to resources Recommend Favorite

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results

By Pacini P.   Rinaldini M.   Algeri R.   Guarneri A.   Tucci E.   Barsanti G.   Neri B.   Bastiani P.   Marzano S.   Fallai C.  

European Journal of Cancer, Vol. 36, Iss. 8, 2000-05 ,pp. : 966-975

Elsevier

Access to resources Recommend Favorite

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

By Constenla Manuel   Garcia-Arroyo Ramon   Lorenzo Isabel   Carrete Nancy   Campos Begoña   Palacios Patricia  

Gastric Cancer, Vol. 5, Iss. 3, 2002-09 ,pp. : 142-147

Springer Publishing Company

Access to resources Recommend Favorite